- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03970720
Restoration of Hypoglycemia Awareness With Metoclopramide
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypoglycemia is the most prevalent clinical complication in the daily management of diabetes and is the major obstacle to normalizing blood sugar. For people with Type 1 diabetes mellitus (T1DM), hypoglycemia associated autonomic failure (HAAF) increases the risk for severe hypoglycemia by a factor of 25 or more. A major component of HAAF is hypoglycemia unawareness (perhaps more accurately defined as impaired awareness of hypoglycemia), which involves in the loss/diminution of warning symptoms to hypoglycemia that would normally prompt a corrective behavioral response (e.g., eating food). Approximately 25-40% of people with T1DM report hypoglycemia unawareness. This value is most certainly an underestimation, as even people with diabetes who report having intact hypoglycemia, demonstrate impaired awareness of biochemically confirmed hypoglycemia. Although a major clinical problem for people with T1DM, it remains largely unknown what therapeutic agents could possibly be used to treat hypoglycemia unawareness.
With a goal of identifying existing biological compounds that could restore hypoglycemia awareness, laboratory drug screens were conducted using animal models. It was postulated that an ideal drug would markedly enhance the ability to sense hypoglycemia and trigger a potentially life-saving behavioral response (ie, alert the subject to increase food consumption). The vast majority of tested drugs did not restore hypoglycemia awareness (ie, did not restore blunted food intake response to hypoglycemia). Interestingly, of all the drugs tested, the dopamine antagonist metoclopramide consistently restored hypoglycemia awareness in several preclinical experiments. Additionally, metoclopramide also restored the impaired counterregulatory response to hypoglycemia in the animal model of HAAF.
This pilot phase II clinical trial (with placebo control) will be conducted to determine if FDA approved doses of Metaclopramdide can restore both, 1) hypoglycemia awareness, and 2) the sympathoadrenal response to hypoglycemia in patients with T1DM and hypoglycemia unawareness.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Simon Fisher, MD, PhD
- Phone Number: 859-562-07473
- Email: sjfi230@uky.edu
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40516
- Recruiting
- University of Kentucky
-
Contact:
- Simon Fisher, MD, PhD
-
Contact:
- Kennedi Hall, MPH
- Phone Number: 7778 8593232232
- Email: Kennedi.Hall@uky.edu
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Completed
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects with Type 1 Diabetes Mellitus
- Diabetes duration > 5 years
- Hemoglobin A1c ≤ 9%
- Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines
Exclusion Criteria:
- History of myocardial infarction, cardiac arrhythmia, congestive heart failure and coronary artery insufficiency
- History of stroke or brain disease
- History of genitourinary obstruction or urinary retention
- Advanced liver disease
- Active anemia with hemoglobin less than 11 g/dL
- Female in pregnancy or breastfeeding, or not able to practice effective contraception during the study period
- Uncontrolled mania or active major depressive disorder
- Previous allergic reaction or side effect to heparin use
- Contraindications to metoclopramide or conditions raising the risk for complication development to metoclopramide, such as hypersensitivity to metoclopramide, ongoing mechanical gastrointestinal obstruction, uncontrolled hypertension, pheochromocytoma, seizure disorders, Parkinson's disease, use of neuroleptics or antipsychotics within 6 months, use of benzodiazepines within the last month, active or recent (last 14 days) use of monoamine oxidase inhibitors or opioids, active alcohol or drug abuse, or other sedatives
- Participation in another study evaluating treatment for impaired awareness of hypoglycemia or hypoglycemia-associated autonomic failure in the last 30 days
- Current use of unblinded real-time Continuous Glucose Monitoring System
- Frequent need of acetaminophen administration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T1DM - Unaware: Metoclopramide
T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg metoclopramide four times a day during the four-week intervention period.
|
10 mg metoclopramide four times a day
|
Placebo Comparator: T1DM - Unaware: Placebo
T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
|
10 mg matching placebo capsules four times a day
|
Placebo Comparator: T1DM - Aware: Placebo
T1DM participants with hypoglycemia awareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
|
10 mg matching placebo capsules four times a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Blood Glucagon
Time Frame: 4 weeks
|
Blood samples will be drawn from study participants during the initial hypoglycemic clamp study (Day 0) and during the second hypoglycemic clamp study (Day 28) following the 4-week intervention period.
The average change in blood glucagon level will be compared between the study arms.
|
4 weeks
|
Change in Blood Epinephrine
Time Frame: 4 weeks
|
Blood samples will be drawn from study participants during the initial hypoglycemic clamp study (Day 0) and during the second hypoglycemic clamp study (Day 28) following the 4-week intervention period.
The average change in blood epinephrine level will be compared between the study arms.
|
4 weeks
|
Change in Blood Norepinephrine
Time Frame: 4 weeks
|
Blood samples will be drawn from study participants during the initial hypoglycemic clamp study (Day 0) and during the second hypoglycemic clamp study (Day 28) following the 4-week intervention period.
The average change in blood norepinephrine level will be compared between the study arms.
|
4 weeks
|
Change in Blood Cortisol
Time Frame: 4 weeks
|
Blood samples will be drawn from study participants during the initial hypoglycemic clamp study (Day 0) and during the second hypoglycemic clamp study (Day 28) following the 4-week intervention period.
The average change in blood cortisol level will be compared between the study arms.
|
4 weeks
|
Change in Blood Pancreatic Polypeptide
Time Frame: 4 weeks
|
Blood samples will be drawn from study participants during the initial hypoglycemic clamp study (Day 0) and during the second hypoglycemic clamp study (Day 28) following the 4-week intervention period.
The average change in blood pancreatic polypeptide level will be compared between the study arms.
|
4 weeks
|
Change in Hypoglycemia Symptom Recognition
Time Frame: 4 weeks
|
Participant's self-reported symptoms of hypoglycemia will be obtained during the initial hypoglycemic clamp study (Day 0) and during the second hypoglycemic clamp study (Day 28) following the 4-week intervention period.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes
Time Frame: 6 weeks
|
Participants will complete a report of all hypoglycemic events during the study surveillance periods.
The average ratio of self-reported hypoglycemic episodes to total hypoglycemic episodes recorded by Continuous Glucose Monitoring (CGM) during these periods will be compared between the study arms.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Simon Fisher, MD, PhD, University of Kentucky
Publications and helpful links
General Publications
- Cryer PE. Hypoglycemia-associated autonomic failure in diabetes. Handb Clin Neurol. 2013;117:295-307. doi: 10.1016/B978-0-444-53491-0.00023-7.
- Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013 Jul 25;369(4):362-72. doi: 10.1056/NEJMra1215228. No abstract available.
- Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991 Feb;40(2):223-6. doi: 10.2337/diab.40.2.223.
- Schultes B, Schmid SM, Wilms B, Jauch-Chara K, Oltmanns KM, Hallschmid M. Lactate infusion during euglycemia but not hypoglycemia reduces subsequent food intake in healthy men. Appetite. 2012 Jun;58(3):818-21. doi: 10.1016/j.appet.2012.01.022. Epub 2012 Jan 28.
- Schmid SM, Jauch-Chara K, Hallschmid M, Oltmanns KM, Born J, Schultes B. Short-term nocturnal hypoglycaemia increases morning food intake in healthy humans. Diabet Med. 2008 Feb;25(2):232-5. doi: 10.1111/j.1464-5491.2007.02347.x.
- Dewan S, Gillett A, Mugarza JA, Dovey TM, Halford JC, Wilding JP. Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal. Diabetes Metab Res Rev. 2004 Sep-Oct;20(5):405-10. doi: 10.1002/dmrr.471.
- Towler DA, Havlin CE, Craft S, Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993 Dec;42(12):1791-8. doi: 10.2337/diab.42.12.1791.
- Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2008 Apr;25(4):501-4. doi: 10.1111/j.1464-5491.2008.02413.x.
- Kubiak T, Hermanns N, Schreckling HJ, Kulzer B, Haak T. Assessment of hypoglycaemia awareness using continuous glucose monitoring. Diabet Med. 2004 May;21(5):487-90. doi: 10.1111/j.1464-5491.2004.1136.x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Hypoglycemia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Dopamine Agents
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Metoclopramide
Other Study ID Numbers
- IRB_00118549
- 1R01DK118082-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoglycemia Unawareness
-
University of Alabama at BirminghamBirmingham Fire and Rescue ServiceCompletedDiabetes Mellitus | Hypoglycemia | Hypoglycemia Unawareness | Hypoglycemia AcuteUnited States
-
Owen Chan, PhDTerminated
-
Radboud University Medical CenterCompletedDiabetes | Hypoglycemia UnawarenessNetherlands
-
Institut de Recherches Cliniques de MontrealRecruitingType 1 Diabetes | Hypoglycemia UnawarenessCanada
-
University of MinnesotaCompletedType 1 Diabetes | Hypoglycemia UnawarenessUnited States
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHealthy | Type 1 Diabetes | Hypoglycemia UnawarenessUnited States
-
University of MinnesotaCompletedType 1 Diabetes | Hypoglycemia UnawarenessUnited States
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Active, not recruitingHypoglycemia | Type1diabetes | Islet Cell Transplantation | Hypoglycemia UnawarenessUnited States
-
University of MinnesotaTerminatedType 1 Diabetes | Hypoglycemia UnawarenessUnited States
Clinical Trials on Metoclopramide
-
Ikechukwu Bartholomew UlasiCompletedIleus PostoperativeNigeria
-
Adiyaman University Research HospitalCompleted
-
Mount Sinai Hospital, CanadaWithdrawnin Vitro Fertilization | Poor ResponderCanada
-
University Hospital, BordeauxCompleted
-
Vancouver General HospitalUnknownPost Concussive Syndrome | Post Concussive HeadacheCanada
-
National Center for Research Resources (NCRR)Children's Hospital of PhiladelphiaCompletedInfant, Newborn, DiseasesUnited States
-
The Hospital for Sick ChildrenThe Physicians' Services Incorporated FoundationTerminated
-
Ain Shams UniversityUnknownCritically-ill PatientsEgypt
-
Pamukkale UniversityCompletedNausea | Akathisia
-
National University Hospital, SingaporeCompletedBreastfeedingSingapore